Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

968.00DKK
10:59am EDT
Price Change (% chg)

kr.-7.00 (-0.72%)
Prev Close
kr.975.00
Open
kr.979.50
Day's High
kr.985.50
Day's Low
kr.965.00
Volume
648,183
Avg. Vol
689,163
52-wk High
kr.1,100.00
52-wk Low
kr.848.00

NOVOb.CO

Chart for NOVOb.CO

About

Novo Nordisk A/S is a Denmark-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company reports two business segments: Diabetes care and Biopharmaceuticals. The Diabetes care division offers a range of diabetes products, including insulin pens and needles, such as... (more)

Overall

Beta: 0.47
Market Cap (Mil.): kr.431,450.00
Shares Outstanding (Mil.): 442.51
Dividend: 18.00
Yield (%): 1.85

Financials

  NOVOb.CO Industry Sector
P/E (TTM): 23.47 38.06 37.87
EPS (TTM): 41.55 -- --
ROI: 59.84 19.42 18.70
ROE: 68.77 20.10 19.53
Search Stocks

India's Sun Pharma gets FDA approval for diabetes generic drug

July 12 - India's Sun Pharmaceutical Industries said on Friday it has received final approval from the United States Food and Drug Administration (FDA) to launch the generic version of Novo Nordisk's Prandin diabetes drug.

11 Jul 2013

Celebrity chef Paula Deen loses more deals, but book sales soar

LOS ANGELES - U.S. celebrity chef Paula Deen saw more lucrative deals evaporate on Thursday despite her renewed apologies for using a racial slur, as retailer Target Corp and drug company Novo Nordisk A/S joined the list of sponsors distancing themselves from the doyenne of Southern cooking.

27 Jun 2013

Celebrity chef Paula Deen loses more deals, but book sales soar

LOS ANGELES, June 27 - U.S. celebrity chef Paula Deen saw more lucrative deals evaporate on Thursday despite her renewed apologies for using a racial slur, as retailer Target Corp and drug company Novo Nordisk A/S joined the list of sponsors distancing themselves from the doyenne of Southern cooking.

27 Jun 2013

RPT-Fitch Affirms 4 STFC's ABS PTCs at 'BBB-sf'; Outlook Stable

June 21 - (The following statement was released by the rating agency)

21 Jun 2013

Denmark's Novo Nordisk says S&P lifts its credit rating

COPENHAGEN, June 19 - Denmark's Novo Nordisk , the world's biggest insulin producer, has had its long-term corporate credit rating raised by Standard & Poor's to "AA-" from "A+", with a stable outlook, the company said.

19 Jun 2013

U.S. court finds Novo Nordisk Prandin diabetes drug patent invalid

- A U.S. appeals court found the patent on Novo Nordisk's Prandin diabetes drug in combination with metformin to be invalid, paving the way for introduction of a generic version of the medicine, the Danish drugmaker said on Tuesday.

18 Jun 2013

US court finds Novo Nordisk Prandin diabetes drug patent invalid

June 18 - A U.S. appeals court found the patent on Novo Nordisk's Prandin diabetes drug in combination with metformin to be invalid, paving the way for introduction of a generic version of the medicine, the Danish drugmaker said on Tuesday.

18 Jun 2013

Novo Nordisk shares hit by concerns over rival diabetes drugs

COPENHAGEN - Novo Nordisk , the world's biggest insulin producer, faces more competition in the diabetes field from rivals Eli Lilly and Sanofi , both of which will showcase new products at an upcoming medical meeting.

17 Jun 2013

UPDATE 1-NORDIC STOCKS - Factors to watch on June 17

HELSINKI, June 17 - The following stocks may be affected by newspaper reports and other factors on Monday:

17 Jun 2013

Novo Nordisk hit by near $1 billion transfer pricing tax claim: TV

COPENHAGEN - Novo Nordisk , the world's biggest insulin producer, is facing a tax claim for 5.5 billion Danish crowns ($975 million) from the Danish authorities in a dispute over transfer pricing, local television broadcaster DR said on Monday.

10 Jun 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Plunkett Research, Ltd.
$99.00
Provider: Reuters Investment Profile
$20.00
Provider: Pechala's Reports
$15.00
Provider: Plunkett Research, Ltd.
$99.00
Provider: TheStreet.com Ratings
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks